Key clinical point: Radioactive iodine therapy linked to increased risk of solid cancer death.
Major finding: Around 8% of solid cancer deaths among patients who have undergone radioactive iodine therapy might be attributed to the radiation.
Study details: Longitudinal cohort study in 18,805 individuals with hyperthyroidism.
Disclosures: The study was funded by the National Cancer Institute. One author declared membership of a consortium supported by the pharmaceutical sector.
Kitahara C et al. JAMA Internal Medicine 2019, July 1. DOI:10.1001/jamainternmed.2019.0981.